The first-in-class bispecific antibody IBI318 (LY3434172) targeting PD-1 and PD-L1 in patients with advanced tumors: a phase Ia/Ib study

ABSTRACT:

SUBMITTER: Ruan D 

PROVIDER: S-EPMC11606118 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature